For Media and Investors only 


  • Classical Pride concert to take place in conjunction with GAY TIMES
  • Curated by conductor Oliver Zeffman, all proceeds to go to LGBT+ charities

London, 27 April 2023 – ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced a partnership with GAY TIMES to bring a unique classical concert to celebrate Pride, taking place on 7 July 2023 in the Barbican Hall.

Conceived and curated by conductor Oliver Zeffman, Classical Pride will be the first time any major arts institution in the UK or Europe has hosted a classical orchestral concert for Pride.

Queer composers have contributed enormously to the vast body of classical music we hear in our concert halls and opera houses. This concert will celebrate the diversity of the LGBT+ musical community, featuring performances from trailblazing classical stars including Pavel Kolesnikov, Samson Tsoy, Davóne Tines, Nicky Spence and Ella Taylor. The City of Birmingham Symphony Orchestra will be joined by an LGBT+ community choir, specially assembled for the occasion. Oliver Zeffman will lead them in works by Tchaikovsky, Poulenc, Bernstein, Caroline Shaw and a new commission from British composer Julian Anderson.

Deborah Waterhouse, CEO, ViiV Healthcare and Chair of GSK’s LGBT+ Council said: “The arts have long played an important role in shining a light on the LGBT+ community and we’re proud to partner with Oliver Zeffman and GAY TIMES on this truly ground-breaking event. It’s so important that companies like ViiV and GSK continue to play their part in championing diversity, equity and inclusion and events like Classical Pride provide a fantastic platform to do so.”

Oliver Zeffman said: “I’m hugely excited to be conducting the very first professional orchestral classical Pride concert. There is still so much progress to be made with LGBT+ rights – at home and across the world – and a concert celebrating the community’s enormous contribution to classical music feels long overdue.”

Josh Fletcher, Executive Creative Director, GAY TIMES said: "At GAY TIMES, championing and elevating LGBT+ artists from all disciplines has been at the forefront of both our online and experiential strategies. Classical Pride allows us to expand the genre's presence across the community, ensuring we're creating space for the community to celebrate Pride in a variety of ways. Music will always have a unique ability to bring people together, and we look forward to seeing even more queer talent take to the stage for the UK’s first classical concert for Pride.”

Classical Pride, where ViiV Healthcare is the headline sponsor, is also supported by MasterCard and Little Greene with all proceeds from the concert going to LGBT+ charities – Terrence Higgins Trust, GiveOut (via Amplifund) and Rainbow Railroad.

About ViiV Healthcare

ViiV Healthcare is a global specialist HIV company established in November 2009 by GSK (LSE: GSK) and Pfizer (NYSE: PFE) dedicated to delivering advances in treatment and care for people living with HIV and for people who are at risk of acquiring HIV. Shionogi became a ViiV shareholder in October 2012. The company’s aims are to take a deeper and broader interest in HIV and AIDS than any company has done before and take a new approach to deliver effective and innovative medicines for HIV treatment and prevention, as well as support communities affected by HIV.

For more information on the company, its management, portfolio, pipeline, and commitment, please visit

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at

ViiV Healthcare enquiries:
Media enquiries: Rachel Jaikaran +44 (0) 78 2352 3755 (London)
  Melinda Stubbee +1 919 491 0831 (North Carolina)
  Audrey Abernathy +1 919 605 4521 (North Carolina)
GSK enquiries:
Media enquiries: Tim Foley +44 (0) 20 8047 5502 (London)
  Simon Moore / Dan Smith +44 (0) 20 8047 5502
  Kathleen Quinn +1 202 603 5003 (Washington DC)
  Lyndsay Meyer +1 202 302 4595 (Washington DC)
  Alison Hunt +1 540 742 3391 (Washington DC)
Investor Relations: Nick Stone +44 (0) 7717 618834 (London)
  James Dodwell +44 (0) 20 8047 2406 (London)
  Mick Readey +44 (0) 7990 339653 (London)
  Josh Williams +44 (0) 7385 415719 (London)
  Camilla Campbell +44 (0) 7803 050238 (London)
  Steph Mountifield +44 (0) 7796 707505 (London)
  Jeff McLaughlin +1 215 751 7002 (Philadelphia)
  Frannie DeFranco +1 215 751 4855 (Philadelphia)

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, GSK’s Q4 Results for 2022 and any impacts of the COVID-19 pandemic.

Registered in England & Wales:

GSK plc                                ViiV Healthcare Limited
No. 3888792                        No. 06876960

Registered Office:

980 Great West Road
Brentford, Middlesex

Media contacts

For our corporate press office, email: Rachel Jaikaran

OR call +44 7823 523 755

For US-specific media enquiries, email: Audrey Abernathy

OR call +1 919 605 4521

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at or search for MHRA Yellowcard in the Google Play or Apple App store. By reporting side effects, you can help provide more information on the safety of this medicine.

If you are from outside the UK, you can report adverse events to GSK/ViiV by selecting your region and market, here.